2 ms·
Related: California governor vetoes bill that would have set a $35 cap for insulin - https://news.ycombinator.com/item?id=37815862 https://news.ycombinator.com
by toomuchtodo 1y ago
Related:
California governor vetoes bill that would have set a $35 cap for insulin - https://news.ycombinator.com/item?id=37815862 https://news.ycombinator.com/item?id=37815862 - October 2023 (139 comments)
California’s Plan for Cheaper Insulin Collides with Big Pharma’s Price Cuts - https://news.ycombinator.com/item?id=35325942 https://news.ycombinator.com/item?id=35325942 - March 2023 (2 comments)
California's Own Brand of Insulin - https://news.ycombinator.com/item?id=35220390 https://news.ycombinator.com/item?id=35220390 - March 2023 (0 comments)
Insulin is way too expensive. California has a solution: Make its own - https://news.ycombinator.com/item?id=34726726 https://news.ycombinator.com/item?id=34726726 - February 2023 (258 comments)
California aims to make its own insulin brand to lower price - https://news.ycombinator.com/item?id=32311465 https://news.ycombinator.com/item?id=32311465 - August 2022 (29 comments)
Governor Newsom announces California will make its own insulin - https://news.ycombinator.com/item?id=32021868 https://news.ycombinator.com/item?id=32021868 - July 2022 (216 comments)
California aims to slash insulin prices - https://news.ycombinator.com/item?id=31649237 https://news.ycombinator.com/item?id=31649237 - June 2022 (208 comments)
- JumpCrisscross 1y ago> bill that would have set a $35 cap for insulin Because this worked so well for home insurance. $35 in 2025 dollars buys as much as $32.92 in 2023 dollars [1]. At what point does it become unprofitable for anyone to manufacture and deliver? (Not the out-of-patent stuff nobody wants to take that can be made for $3/vial. The long-acting and ultra-fast formulations people actually use when given a choice.) And unlike with home insurance, in an insulin shortage, people die. You need a CalFIRE mechanism, a seller of last resort, who will purchase the insulin at any price on the market and sell it at $35 for such a scheme to work. State-controlled production removes that surprise factor. It's a much better system than price regulation. [1] https://www.usinflationcalculator.com https://www.usinflationcalculator.com
- deleted 1y ago[deleted]
- hodgehog11 1y agoThe difference is that the proposed caps for home insurance would have made the product unprofitable, no question. My understanding is that there is no way any vial of insulin anywhere, at this point in time, should cost enough to produce for US$35 asking price to be unprofitable. See [1] and [2] for example. This would need to increase with inflation, of course. Regardless, the bill didn't pass. Arguments like this were probably the reason why. [1] https://www.mayoclinicproceedings.org/article/S0025-6196(21)00883-1/abstract https://www.mayoclinicproceedings.org/article/S0025-6196(21)... [2] https://www.medcentral.com/endocrinology/diabetes/the-high-costs-of-insulin https://www.medcentral.com/endocrinology/diabetes/the-high-c...
- dragonwriter 1y ago> My understanding is that there is no way any vial of insulin anywhere, at this point in time, should cost enough to produce for US$35 asking price to be unprofitable. The vetoed bill (SB 90 of 2023) did not address the price of insulin, only the allowable insurance copay for insulin. The fact that this, without addressing the actual price, would just shift the costs from copays to premiums was called out in the veto message. Also note that, with CalRx's insulin initiative ready to deliver at the same time the bill goes into effect, SB 40 of 2025 which set the same copay cap as SB 90 of 2023, was signed by Newsom this week.
- jrflowers 1y ago> The long-acting and ultra-fast formulations people actually use when given a choice. The patent for insulin glargine (Lantus) and insulin aspart (NovoLog) expired over a decade ago, though kind of amusingly Sanofi holds an active patent on “putting more Lantus in a vial than you usually would” https://patents.google.com/patent/US9345750B2/en https://patents.google.com/patent/US9345750B2/en I could be wrong but off the top of my head the only insulin I can think of that’s probably under patent is Afrezza, which is cool as hell because it’s inhalable and ultra-quick
- JumpCrisscross 1y agoIt’s less the patent per se than the production cost. A lot of cost estimates use the 1980s Humalin or whatnot as their baseline. I’m not diabetic. But everyone I know who is doesn’t like that one. So we need to know the cost for the medicines folks are actually taking.
- jrflowers 1y agoIt looks like the cost to manufacture modern biosimilars could be around $2-6 per vial. https://gh.bmj.com/content/3/5/e000850 https://gh.bmj.com/content/3/5/e000850
- s1artibartfast 1y agoCost to manufacture obviously isnt the only factor.
- Teever 1y agoWhat if the price cap was set at whatever Canadians pay for insulin? It seems like insulin is a lot more affordable there and it's obviously an economically sustainable rate because companies keep selling it to Canada. How much does it cost in Canada anyways?
- TimBurman 1y agoFast Acting Humalog 1000 unit (10 ml) vials cost CAD $40.34 = USD $28.73 in Alberta. Anyone can get Blue Cross from the government which is CAD $720 a year. Then each 3 month supply of a prescription like insulin has a co-pay of $28 a quarter, for however many vials you need. I last used Lantus 24 hour insulin in 2020, when it was around CAD $60, but the government has been switching to biosimilar brands and providing free insulin pumps and supplies including test strips, which only use fast acting insulins. Lantus is most similar to this California insulin.
- dragonwriter 1y agoIt's worth noting that the veto message on the 2023 bill (which did not cap insulin prices, but only insurance copays for insulin) explicitly called out the CalRx project as providing the real solution, and noted that capping copays without addressing actual drug costs would result in the actual price just getting passed on to consumers via insurance premiums. It is also worth noting that this week Newsom signed SB 40 0f 2025, which did exactly the same thing in this area as the vetoed SB 90 of 2023, no doubt because the price side was also being adddressed simultaneously, with CalRx insulin to be on available in January when SB 40 goes into effect.